Holen Sie sich die Stockscreener-App
47.50
3.26%
1.50
Handel nachbörslich:
47.00
-0.50
-1.05%
Schlusskurs vom Vortag:
$46.00
Offen:
$47.38
24-Stunden-Volumen:
1.22M
Relative Volume:
1.44
Marktkapitalisierung:
$10.56B
Einnahmen:
$1.97B
Nettoeinkommen (Verlust:
$92.93M
KGV:
116.82
EPS:
0.4066
Netto-Cashflow:
$459.60M
1W Leistung:
+4.24%
1M Leistung:
+6.34%
6M Leistung:
+14.32%
1J Leistung:
+2.06%
1-Tages-Spanne:
$47.21
$47.61
1-Wochen-Bereich:
$45.10
$47.61
52-Wochen-Spanne:
$39.03
$47.61
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
47.50 | 10.56B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen (NYSE:QGEN) Hits New 1-Year HighHere's What Happened - MarketBeat
Qiagen stock hits 52-week high at $47.45 amid steady growth - Investing.com
Genetic Testing Market Projected To Witness Substantial Growth, 2025-2032: Eurofins Scientific, Illumina Inc., - EIN News
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research - GlobeNewswire Inc.
QGEN Stock Might Rise Following Partnership With Genomics England - MSN
Strategic Collaborations Aid QGEN Stock Amid Competition - Yahoo Finance
Qiagen (NYSE:QGEN) Short Interest Update - MarketBeat
QIAGEN Finalizes $300 Million Synthetic Share Repurchase Plan - TipRanks
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million - Silicon Canals
QIAGEN Announces $300M Share Repurchase Plan with Reverse Stock Split, $1.26 Per Share Payout - StockTitan
Qiagen Announces BlackRock’s Significant Voting Rights in Recent AFM Disclosure - TipRanks
Qiagen N.V. Voting Rights Update: BlackRock’s Significant Stake Disclosed - TipRanks
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast - BioSpace
QIAGEN Sets Q4 2024 Earnings Release Date: Conference Call Details Announced - StockTitan
Qiage announces $300M buyback plan - MSN
Qiagen N : Ad hoc Announcement according to Art. 17 Market Abuse Regulation - Marketscreener.com
QIAGEN Announces $300 Million Synthetic Share Repurchase Plan - TipRanks
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples - Marketscreener.com
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase - BioSpace
New Product Offerings Support QIAGEN's Shares Amid Currency Woes - MSN
QIAGEN Unveils New $300M Share Buyback Plan, Accelerating $1B Shareholder Return Strategy - StockTitan
Qiagen Announces BlackRock’s Significant Stake in Company - TipRanks
Qiagen N.V.'s (NYSE:QGEN) Share Price Not Quite Adding Up - Simply Wall St
QGENQIAGEN N.V. Latest Stock News & Market Updates - StockTitan
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights from Biological Samples - Marketscreener.com
QIAGEN Doubles Digital PCR Capabilities: QIAcuity Now Analyzes 12 Targets Simultaneously - StockTitan
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care - DutchNews.nl
QIAGEN Secures FDA Clearance for Groundbreaking Rapid Gastrointestinal Test Panel - StockTitan
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Qiagen (NYSE:QGEN) Receives $51.50 Consensus Target Price from Brokerages - MarketBeat
BlackRock’s Significant Stake Announcement in Qiagen - TipRanks
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content - sharewise
Qiagen (NYSE:QGEN) Given Equal Weight Rating at Morgan Stanley - MarketBeat
Qiagen stock downgrade: Morgan Stanley says outperformance may be capped By Investing.com - Investing.com South Africa
Tuberculosis Diagnostics Market Opportunities and Strategies to 2033, Key Companies Include Beckton, Dickinson and Co, Qiagen, F. Hoffmann-La Roche, bioMerieux, and Danaher - Yahoo Finance
Qiagen stock downgrade: Morgan Stanley says outperformance may be capped - Investing.com
Morgan Stanley Downgrades Qiagen NV (QGEN) to Equalweight - StreetInsider.com
JPMorgan Chase & Co. Raises Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
Qiagen N.V. Discloses BlackRock’s Voting Rights Notification - TipRanks
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - MSN
BlackRock Increases Voting Influence in Qiagen - TipRanks
Why Is Qiagen N.V. (QGEN) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):